Prion proteins meet protein quality control

Trends in Cell Biology

Volumn 13, Issue 7, 2003, Pages 337-340

  Dimcheff, Derek E ^a   Portis, John L ^a   Caughey, Byron ^a  

^a Division of Intramural Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PRION PROTEIN; PROTEASOME; PROTEASOME INHIBITOR;

AMINO ACID SEQUENCE; APOPTOSIS; CELL DEATH; CELL PROTECTION; CELL STRUCTURE; CLINICAL FEATURE; CYTOSOL; DISEASE COURSE; HUMAN; INHIBITION KINETICS; NERVE DEGENERATION; NEUROTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; QUALITY CONTROL; REVIEW;

EID: 0038094427     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(03)00125-9     Document Type: Review

References (17)

1. Kocisko D.A., et al. Cell-free formation of protease-resistant prion protein. Nature. 370:1994;471-474.
2. Saborio G.P., et al. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 411:2001;810-813.
3. Ma J., Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14955-14960.
4. Ma J., et al. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 298:2002;1781-1785.
5. Ma J., Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science. 298:2002;1785-1788.
6. Caughey B., et al. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 65:1991;6597-6603.
7. Harris D.A. Biosynthesis and cellular processing of the prion protein. Adv. Protein Chem. 57:2001;203-228.
8. Bonifacino J.S., Weissman A.M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu. Rev. Cell Dev. Biol. 14:1998;19-57.
9. Bence N.F., et al. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
10. Drisaldi B., et al. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J. Biol. Chem. 2003;. DOI: 101074/jbcM213247200.
11. Petrucelli L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 36:2002;1007-1019.
12. Imai Y., et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 105:2001;891-902.
13. Nishitoh H., et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 16:2002;1345-1355.
14. Kaufman R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 13:1999;1211-1233.
15. Chiesa R., Harris D.A. Prion diseases: what is the neurotoxic molecule? Neurobiol. Dis. 8:2001;743-763.
16. Gu Y., et al. Mutant prion protein-mediated aggregation of normal prion protein in the endoplasmic reticulum: implications for prion propagation and neurotoxicity. J. Neurochem. 84:2003;10-22.
17. Jesenberger V., Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 3:2002;112-121.